Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors

by | 12 Nov Tue | English

Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023) rounds, Jeito’s renewed commitment demonstrates its strategy of supporting promising portfolio companies through key value-creation milestones. Financing will advance...

Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease

by | 22 May Wed | English

Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion which illustrates that HI-Bio™, with Jeito’s ongoing strategic and operational support, has achieved significant progress in its late-stage clinical programs. This...

Jeito Capital strengthens its Executive Committee with the appointment of Sarah Leroy who is taking the newly created position of Secretary General responsible for managing Legal and Financial Affairs, Compliance, HR and Sustainability

by | 14 Mar Thu | English

Paris, France, March 14th 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the appointment of Sarah Leroy who is taking the newly created position of Secretary General...